OncoGenex Technologies Inc. Cuts IPO to $7.50-$8.50 Per Share

WASHINGTON, March 1 (Reuters) - OncoGenex Technologies Inc., a Canadian biopharmaceutical firm focused on new cancer therapies, on Thursday cut its planned initial public offering to $7.50 to $8.50 per share from a previous range of $10 to $12.

>>> Discuss This Story